The Clinical Outcomes of Stem Cell Therapy for Decompensated Liver Disease: A Systematic Review and Meta-Analysis

Worldwide, many patients with decompensated liver disease cannot get timely liver transplantation due to the shortage of the liver donors. In this case, stem cell therapy seems to be an alternative for patients with end stage liver disease. The aim of this article is to conduct a meta-analysis to evaluate the effectiveness of stem cell transplantation in patients with decompensated liver disease. Medline, Embase and Cochrane Library were searched for relevant studies. Only controlled trials were enrolled in this meta-analysis. Random effect model or fixed effect model will be used to analyze the collected data depending on the heterogeneity of the pooled studies. Review Manager 5.3 was used for statistical analysis. 8 publications involving 9 controlled studies were included in the final analysis. The studies were conducted in China, Iran, Egypt and India. Cell transplantation did not change the level of serum albumin and model for end stage liver disease score at 12 w and 24 w. Furthermore, no matter at 12 w or 24 w, the serum level of total bilirubin showed statistical decline. However, alanine transaminase, aspartate transaminase and prothrombin activity were improved significantly at 12 w, but this change was not obvious at 24 w. Stem cell transplantation showed some desirable outcomes in a relatively short term. However, many hepatic parameters did not last in the long term. Further studies are needed to explore the efficacy in patients with decompensated liver disease.

[1]  Zhiliang Gao,et al.  The efficacy and long-term safety of autologous bone marrow stem cells transplantation in patients with hepatitis B virus-associated decompensated liver cirrhosis , 2017 .

[2]  R. Malekzadeh,et al.  Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients With Decompensated Cirrhosis: A Double‐Blind Randomized Controlled Trial , 2016, Stem cells translational medicine.

[3]  Shun Zhang,et al.  Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis , 2015, Hepatitis monthly.

[4]  D. Nageshwar Reddy,et al.  Autologous mobilized peripheral blood CD34(+) cell infusion in non-viral decompensated liver cirrhosis. , 2015, World journal of gastroenterology.

[5]  A. Bahnassy,et al.  Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease , 2014, Stem Cell Research & Therapy.

[6]  R. Malekzadeh,et al.  Randomized placebo‐controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Zheng Zhang,et al.  [Prospective controlled trial of safety of human umbilical cord derived-mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis]. , 2012, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[8]  L. Peng,et al.  Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short‐term and long‐term outcomes , 2011, Hepatology.

[9]  C M Habibullah,et al.  Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. , 2010, Cell transplantation.

[10]  Samah M. Abdel-Hamid,et al.  Phase I Trial: Mesenchymal Stem Cells Transplantation in End Stage Liver Disease , 2010 .